10-Q: Paysign Q2 2025 Earnings Soar on Pharma Growth

Paysign, Inc. reported a significant increase in net income and gross profit for Q2 2025, driven by robust growth in its pharma patient affordability programs.

Summary

• Total revenues for the three months ended June 30, 2025, increased by 33.1% to $19.08 million, up from $14.33 million in the prior year period.
• Pharma industry revenue surged by 189.9% to $7.75 million in Q2 2025, compared to $2.67 million in Q2 2024, primarily due to 33 net programs launched in 2024 and 7 new programs in Q2 2025.
• Plasma industry revenue decreased by 4.7% to $10.74 million in Q2 2025, from $11.27 million in Q2 2024, attributed to normalized plasma inventory levels, despite the addition of 123 net plasma centers.
• Net income for Q2 2025 more than doubled to $1.39 million, a 99.1% increase from $0.70 million in Q2 2024.
• Gross profit for Q2 2025 rose by 55.0% to $11.76 million, with gross margin improving to 61.6% from 52.9% in the prior year.
• The company completed the acquisition of Gamma Innovation LLC on March 19, 2025, for a total preliminary purchase consideration of $15.56 million, including cash, future cash payments, equity, and earn-out contingent consideration.
• Adjusted EBITDA for Q2 2025 increased to $4.51 million from $2.24 million in Q2 2024, with Adjusted EBITDA margin expanding to 23.7% from 15.6%.
• The company's cash and restricted cash balance at June 30, 2025, was $113.91 million, with $11.75 million in unrestricted cash.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and net income growth, primarily driven by its high-margin pharma segment. The successful integration of Gamma Innovation and positive liquidity outlook contribute to a very positive sentiment, despite a decline in plasma revenue.

Positives

• Significant revenue growth of 33.1% in Q2 2025 and 36.9% for the six months ended June 30, 2025, driven by strong performance in the pharma segment.
• Pharma industry revenue increased by 189.9% in Q2 2025 and 223.3% for the six months, due to new program launches and increased claim processing (over 80% increase in Q2, over 110% increase in H1).
• Net income nearly doubled in Q2 2025 (99.1% increase) and increased by 294.9% for the six months ended June 30, 2025, demonstrating improved profitability.
• Gross profit increased by 55.0% in Q2 2025 and 61.4% for the six months, with gross margin expanding significantly due to the higher-margin pharma business.
• Income from operations showed a substantial improvement, turning a loss into a profit for the six-month period and increasing over 1000% in Q2.
• Successful acquisition of Gamma Innovation LLC, which is expected to enhance technology and market presence in the blood and plasma collection industry.
• Strong Adjusted EBITDA growth and margin expansion, indicating improved operational efficiency.
• The company believes its available cash on hand, excluding restricted cash, along with forecast revenues and cash flows, will be sufficient to sustain operations for the next twenty-four months.

Negatives

• Plasma industry revenue decreased by 4.7% in Q2 2025 and 6.9% for the six months, primarily due to a decline in plasma donations and dollars loaded to cards as plasma inventory levels normalized.
• Gross dollar volume loaded on cards decreased by 3.5% for the three months and 4.0% for the six months ended June 30, 2025, reflecting the decline in plasma volumes.
• Other income (interest income, net) decreased by 25.6% in Q2 2025 and 11.7% for the six months, partly due to implied interest expense from the Gamma acquisition and slightly lower interest rates/bank balances.
• Operating expenses increased significantly (38.3% in Q2, 33.2% in H1) due to increased compensation, technology investments, stock-based compensation, and acquisition costs.

Risks

• Concentration of credit risk with cash and restricted cash held primarily with one financial institution, exceeding federally insured limits by approximately $2.35 million at June 30, 2025.
• Concentration of accounts receivable risk, with two pharma patient affordability program customers individually representing 10% and 17% of the accounts receivable balance at June 30, 2025.
• Ongoing stockholder derivative actions alleging breach of fiduciary duty, unjust enrichment, and waste, though a proposed settlement is pending preliminary approval.
• Uncertainties inherent in litigation, with potential for adverse results to harm the business.
• Reliance on estimates and assumptions in financial statements, which could differ from actual results and materially affect financial position and results of operations.
• Potential for changes in estimates and assumptions related to goodwill and purchased intangible assets to materially affect fair value determination and goodwill impairment.

Future Outlook

The company plans to continue investing additional funds in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance in 2025. It evaluates raising capital to diversify into new market verticals but believes internally generated funds will be sufficient to support existing business and expand into new vertical markets if new capital is not raised. The company anticipates its available cash on hand, excluding restricted cash, along with forecast revenues and cash flows, will be sufficient to sustain operations for the next twenty-four months through Q2 2027.

Management Comments

• We do not anticipate any losses with respect to accounts with balances exceeding federally insured limits.
• Our platform can be seamlessly integrated with our clients' systems.
• Our distinctive positioning allows us to provide end-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics, and customer service.
• Our architecture is known for its cross-platform compatibility, flexibility, and scalability allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities.
• We are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals.
• Following the acquisition of Gamma, we are now allocating some of our marketing efforts to selling our donor engagement application and customer resource management product into our existing markets.
• In 2025, we plan to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance.
• From time to time, we evaluate raising capital to enable us to diversify into new market verticals.
• If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds.
• Our available cash on hand, excluding restricted cash, along with our forecast for revenues and cash flows for the remainder of 2025 and through the second quarter of 2027, will be sufficient to sustain our operations for the next twenty-four months.

Industry Context

The company operates in the prepaid card market, which has seen significant growth due to technological advancements, convenience, and flexibility. Its focus on pharma patient affordability programs aligns with a growing need for healthcare reimbursement solutions, while its plasma industry segment faces normalization challenges after a period of high demand. The acquisition of Gamma Innovation LLC indicates a strategic move to enhance its offerings in the blood and plasma collection industry, potentially mitigating the impact of declining plasma donations by improving donor engagement and operational efficiency.

Legal Proceedings

• Securities Class Action (In re Paysign, Inc. Securities Litigation) was preliminarily settled for $3,750,000, fully covered by the company's D&O insurance, and received final court approval on April 18, 2024.
• Four stockholder derivative actions (Andrzej Toczek, John K. Gray, Simone Blanchette, Mo Jeewa) are currently pending and have been consolidated.
• The parties in the stockholder derivative actions agreed in principle to a proposed settlement on October 4, 2024, with a Motion for Preliminary Approval of Derivative Settlement currently pending before the Court as of May 6, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to significant increases in net income, gross profit, and EPS, indicating improved financial health and profitability. The stock repurchase program also benefits shareholders.
• Employees: Increased compensation and benefits, and continued hiring to support growth, particularly in the pharma patient affordability business, suggest positive impact.
• Customers (Pharma): Benefit from expanded program offerings and increased claim processing capabilities, indicating improved service and support.
• Customers (Plasma): May experience changes due to normalized plasma inventory levels and declining donations, though new centers are being added.
• Creditors: Improved financial performance and liquidity position reduce credit risk.

Next Steps

• Continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance in 2025.
• Allocate marketing efforts to selling the newly acquired donor engagement application and customer resource management product into existing markets.
• Complete the final valuation of assets acquired and liabilities incurred from the Gamma Innovation LLC acquisition within the one-year measurement period.
• Monitor the health and soundness of bank relationships in light of recent bank failures.
• Continue to evaluate raising capital to diversify into new market verticals.

Key Dates

Recommendation

The company's Q2 2025 results demonstrate exceptional growth, particularly in the high-margin pharma segment, which has more than offset declines in the plasma business. The substantial increases in revenue, gross profit, net income, and Adjusted EBITDA indicate strong operational leverage and profitability. The successful integration of the Gamma Innovation acquisition further strengthens its market position. While there are ongoing legal proceedings, the securities class action has been settled, and derivative actions are moving towards settlement, mitigating significant immediate legal risks. The company's liquidity position is robust, and management's outlook for sustaining operations for the next 24 months is positive. These factors collectively point to a strong financial trajectory and significant upside potential for investors.

Keywords

Prepaid Cards, Pharma Patient Affordability, Payment Processing, Fintech, Plasma Industry, Corporate Incentives, Digital Banking, SEC Filing, Quarterly Report, Earnings, Acquisition, Gamma Innovation